Rejuvenate Bio

Rejuvenate Bio is a biotechnology company based in San Diego, founded in 2017.

The company focuses on developing combination gene therapies aimed at reversing aging and treating chronic, age-related diseases in both humans and dogs. Its mission is to address multiple age-related conditions, such as heart failure and diabetes, with a single injection, thereby extending healthspan and lifespan. The company specializes in targeted gene delivery to re-regulate gene expression levels altered by aging. Its lead therapy, RJB-01, is a liver-directed gene therapy designed to reduce harmful cytokines and enhance beneficial hormones. Rejuvenate Bio also has a gene therapy for Mitral Valve Disease in dogs and is collaborating with partners like Phibro Animal Health and Merck Animal Health USA to advance its therapies. With a dual-market strategy, the company aims to validate its gene therapy platform in the animal health sector before applying it to human health.